In vitro analysis demonstrates peptide binding to HLA-A*0201 in T2 cells, indicating potential immunotherapeutic targets for estrogen receptor-positive breast cancer.
Peptides bind to HLA-A*0201. T2 cells were pulsed with indicated peptide for 4 hours and surface HLA-A*0201 was stained. MFI of pulsed T2 cells were normalized to experimentally matched non-pulsed T2 cells, and data expressed as fold change in MFI. Dashed horizontal line indicates non-pulsed T2 HLA-A*0201. FLU peptide was used as a positive control HLA-A*0201 peptide known to bind with high affinity. Data represent three independent experiments performed in triplicate. Statistical significance was determined via comparison of pulsed MFI versus non-pulsed raw MFI using unpaired Student t test. ***, P < 0.001.
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: